This study provided a proof-of-concept that intravenous injection of SR717@RGE-HFn NPs effectively activates the STING pathway and exerts immunoregulatory effects within the intracranial glioma TME, leading to the inhibition of tumor progression with excellent biocompatibility. The gene discussed is STING1; the disease is glioma.